Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

ClinicalTrials.gov ID: NCT05591755

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05591755. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Evaluation of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle in an Allergen BioCube® in Subjects With Seasonal Allergic Conjunctivitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

Study identification

NCT ID: NCT05591755
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bausch & Lomb Incorporated; Industry
Enrollment: 229 participants

Conditions and interventions

Conditions

Seasonal Allergic Conjunctivitis

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 18, 2022 (Actual)
Primary completion: Aug 9, 2023 (Actual)
Completion: Aug 9, 2023 (Actual)
Last update posted: Jul 1, 2025

2022 – 2023

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
104 Butchertown Clinical Trials	Louisville	Kentucky	40206	—
101 Andover Eye Associates	Andover	Massachusetts	01810	—
105 - Advancing Vision Research	Goodlettsville	Tennessee	37072	—
102 Total Eye Care, PA	Memphis	Tennessee	38119	—
108 Emerson Clinical Research Institute Inc.	Falls Church	Virginia	22046	—
107 Virginia Eye Institute	Richmond	Virginia	23230	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05591755, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 1, 2025 · Synced Nov 13, 2026